NRx Pharmaceuticals, Inc. (NRXP)
NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.
$18.27M
Mr. Stephen H. Willard Esq.
2.00
Wilmington, DE
Nov 20, 2017
-0.63
$-2.68
0.66
0.87
0.00%
-0.60
-7.67
0.00
0.66
-182.27%
-684.51%
Similar stocks (8)
Nutriband Inc.
NTRB
Longeveron Inc.
LGVN
RenovoRx, Inc.
RNXT
BiomX Inc.
PHGE
Senti Biosciences, Inc.
SNTI
Cingulate Inc.
CING
Quoin Pharmaceuticals, Ltd.
QNRX
Aditxt, Inc.
ADTX
ETF Exposure (5)
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Total Stock Market Index Fund
VITSX
0%
Vanguard Total Stock Market Index Fund
VTI
0%
Vanguard Total Stock Market Index Fund
VTSAX
0%
Vanguard Extended Market Index Fund
VXF
0%
Similar stocks (8)
Nutriband Inc.
NTRB
Longeveron Inc.
LGVN
RenovoRx, Inc.
RNXT
BiomX Inc.
PHGE
Senti Biosciences, Inc.
SNTI
Cingulate Inc.
CING
Quoin Pharmaceuticals, Ltd.
QNRX
Aditxt, Inc.
ADTX
ETF Exposure (5)
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Total Stock Market Index Fund
VITSX
0%
Vanguard Total Stock Market Index Fund
VTI
0%
Vanguard Total Stock Market Index Fund
VTSAX
0%
Vanguard Extended Market Index Fund
VXF
0%